Welcome to our dedicated page for Aeon Biopharma news (Ticker: AEON), a resource for investors and traders seeking the latest updates and insights on Aeon Biopharma stock.
AEON Biopharma develops ABP-450 (prabotulinumtoxinA) as a proposed biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications. Company announcements focus on analytical similarity work, FDA biosimilar pathway interactions, scientific presentations, and the regulatory strategy supporting ABP-450 development.
Recurring AEON updates also address operating and financial results, liquidity and going-concern disclosures, shareholder meeting matters, inducement equity awards, executive and governance changes, capital-structure actions, and NYSE American continued-listing compliance.
AEON Biopharma (NYSE American: AEON) reported Q1 2026 results and a corporate update. The FDA considered its ABP-450 analytical similarity strategy under the 351(k) biosimilar pathway reasonable, supporting advancement toward a comprehensive package.
AEON closed a $6 million PIPE and Daewoong note exchange, cutting debt by over 90%, named John Bencich CFO, reported $6.2 million cash on March 31, 2026, and expects funding into Q3 2026. Planned 2026 milestones include a BPD Type 2b FDA meeting.
AEON Biopharma (NYSE American: AEON) will hold its Annual Shareholder Meeting at 10:00 am PT on June 17, 2026 at the company offices, 5 Park Plaza, Suite 1750, Irvine, CA. Meeting materials are expected on or about April 29, 2026.
The company disclosed an audit going concern qualification for the fiscal year ended December 31, 2025, reflecting its liquidity position as of the audit date. The company expects cash and cash equivalents to fund operations into the third quarter of 2026.
AEON Biopharma (NYSE American: AEON) named John Bencich as Chief Financial Officer and granted inducement equity awards on April 2, 2026. The Compensation Committee approved 754,717 RSUs vesting 25% annually over four years (starting March 9, 2026) and 235,849 PSUs tied to NYSE American compliance.
PSU vesting: 25% at six months after NYSE American notifies the company of regained compliance, then 25% on each of the first three anniversaries of that date, subject to continued service and plan terms.
AEON Biopharma (NYSE: AEON) received an additional NYSE American notice on March 31, 2026, citing noncompliance with Section 1003(a)(ii) after reporting a stockholders' deficit of approximately $55 million as of December 31, 2025.
The company remains listed and subject to an existing compliance Plan through August 3, 2026, and continues trading under the symbol AEON with a ".BC" noncompliance indicator.
AEON (NYSE American: AEON) reported full-year 2025 results and updates on its ABP-450 biosimilar program. Key highlights: analytical data showed 100% amino-acid sequence match to BOTOX® with 93–99% sequence coverage, constructive FDA BPD Type 2a feedback, a $6.0M PIPE plus note exchange reducing debt >90%, and a new CFO appointment.
Cash was $3.0M at year-end 2025; including $4.2M PIPE proceeds, liquidity is expected to fund operations into Q3 2026.
AEON (NYSE American: AEON) reported constructive FDA feedback from a BPD Type 2a meeting in January 2026 on its analytical similarity strategy for ABP-450, a biosimilar to BOTOX. The Agency found AEON’s analytical methodologies reasonable and acknowledged scientific challenges for the 900 kDa toxin complex. AEON plans to complete the majority of its analytical comparability program in 2026 and intends to request a BPD Type 2b meeting in 2026 to discuss next development steps toward full-label approval under the 351(k) pathway.
AEON Biopharma (NYSE: AEON) announced on March 9, 2026 the appointment of John Bencich as Chief Financial Officer. Bencich brings more than 25 years of finance and capital markets experience and will support AEON as it advances ABP-450, a biosimilar to BOTOX, through key regulatory milestones.
His background includes CEO and CFO roles at multiple public biotech companies, capital formation experience, and oversight of clinical and regulatory programs.
AEON (NYSE American: AEON) announced an accepted poster presentation at the 2026 American Academy of Neurology Annual Meeting in Chicago, April 18–22, 2026.
The poster (abstract #4146) presents analytical primary structure comparability between ABP-450 (prabotulinumtoxinA) and onabotulinumtoxinA (Botox), reporting 93.5%–99.3% peptide sequence coverage and no variant peptides across multiple lots. Presenter: Chad K. Oh, M.D.; Date: April 22, 2026; Time: 11:45 am–12:45 pm CT.
AEON (NYSE: AEON) held its scheduled BPD Type 2a meeting with the FDA on Jan. 21, 2026 and is awaiting the official meeting minutes, expected within approximately 30 days, which the company says will inform next steps for development of ABP-450, a biosimilar to BOTOX.
On the same day shareholders approved the November transactions, enabling the Daewoong note exchange to close and substantially reduce outstanding debt, and clearing the way for the second closing of the PIPE financing on or around Jan. 27, 2026 subject to customary closing conditions.
AEON Biopharma (NYSE: AEON) reported inducement grants totaling 392,158 restricted stock units (RSUs) to newly hired non-executive employees, approved under the company’s 2025 Inducement Incentive Plan.
The grants have a grant date of December 11, 2025, vesting commencement dates in December 2025, and vest 25% annually over four years. Awards are subject to the Inducement Plan and individual RSU agreement terms and were issued as inducement material under Section 711 of the NYSE American Company Guide.